Quizartinib
Hematology
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Usuki K, Handa H, Choi I, et al.
Int J Hematol. 2019;110(6):654-664.
Pexidartinib
Other/Multi
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial
Tap WD, Gelderblom H, Palmerini E, et al.
Lancet. 2019;394(10197):478-487.
Quizartinib
Hematology
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial
Cortes JE, Khaled S, Martinelli G, et al.
Lancet Oncol. 2019;20(7):984-997.
T-DXd
Breast Cancer
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study
Tamura K, Tsurutani J, Takahashi S, et al.
Lancet Oncol. 2019;20(6):816-826.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study
Shitara K, Iwata H, Takahashi S, et al.
Lancet Oncol. 2019;20(6):827-836.
Edoxaban
Cardiovascular - AF
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: The ELIMINATE-AF trial
Hohnloser SH, Camm J, Cappato R, et al.
Eur Heart J. 2019;40(36):3013-3021.
Pexidartinib
Other/Multi
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Lee JH, Chen TWW, Hsu CH, et al.
Invest New Drugs. 2020;38(1):99-110.
Edoxaban
Cardiovascular - AF
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 3b trial
Goette A, Merino JL, Ezekowitz MD, et al.
Lancet. 2016;388(10055):P1995-2003.
Edoxaban
Cardiovascular - VTE
Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial
Raskob GE, van Es N, Segers A, et al.
Lancet Haematol. 2016;3(8):e379-e387.
Edoxaban
Cardiovascular - AF
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano RP, Ruff CT, Braunwald E, et al.
N Engl J Med. 2013;369:2093-2104.